Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).

被引：0
|
作者：
Apolo, Andrea Borghese
Lee, Young H.
Cecchi, Fabiola
Agarwal, Piyush K.
Parnes, Howard L.
Khadar, Kattie
Summerell, Amelia
Gulley, James L.
Compton, Kathryn
Figg, William Douglas
Dahut, William L.
Bottaro, Donald P.
机构：
[1] NCI, Bethesda, MD 20892 USA
[2] NCI, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA
[3] NCI, Canc Prevent Div, Bethesda, MD 20892 USA
[4] NCI, Med Oncol Branch, Bethesda, MD 20892 USA
[5] NCI, Mol Pharmacol Sect, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4543
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase 3 randomized study of cabozantinib (XL184) versus everolimus in subjects with dear cell renal cell carcinoma (METEOR)
    Choueiri, Toni K.
    Escudier, Bernard J.
    Les, Thomas Pow
    Cella, David
    Ru, Qinhua C.
    Scheffold, Christian
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)
    Yang, Pei-Wen
    Liu, Yu-Cheng
    Chang, Ya-Han
    Lin, Ching-Ching
    Huang, Pei-Ming
    Hua, Kuo-Tai
    Lee, Jang-Ming
    Hsieh, Min-Shu
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [33] Targeting MET with XL184 to reverse EGFR tyrosine kinase inhibitor (TKI) resistance in NSCLC: impact of preclinical studies on clinical trial design
    Janne, P. A.
    Wax, M.
    Leach, J.
    Engelman, J.
    EJC SUPPLEMENTS, 2008, 6 (12): : 174 - 174
  • [34] A phase 3 randomized study of cabozantinib (XL184) vs everolimus in subjects with clear cell renal cell carcinoma (METEOR)
    Choueiri, T. K.
    Escudier, B.
    Powles, T.
    Cella, D.
    Lee, Y.
    Laird, D. A.
    Scheffold, C.
    Motzer, R. J.
    BJU INTERNATIONAL, 2013, 112 : 4 - 4
  • [35] Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE)
    Smith, Matthew Raymond
    Sweeney, Christopher
    Rathkopf, Dana E.
    Scher, Howard I.
    Logothetis, Christopher
    George, Daniel J.
    Higano, Celestia S.
    Yu, Evan Y.
    Harzstark, Andrea Lynne
    Small, Eric Jay
    Sartor, A. Oliver
    Gordon, Michael S.
    Vogelzang, Nicholas J.
    Smith, David C.
    Hussain, Maha
    De Bono, Johann Sebastian
    Haas, Naomi B.
    Scheffold, Christian
    Lee, Yihua
    Corn, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] Pharmacodynamic and correlative biomarker analyses in clinical trials of XL184, an oral, potent inhibitor of MET, VEGFR2, and RET
    Muller, Thomas
    DePrimo, Samuel
    McGrath, Garth
    Yu, Peiwen
    Wu, Jianming
    Goon, Levina
    Lee, Michelle
    de Costa, Anushka
    Chu, Felix
    Cancilla, Belinda
    Huang, Stephen
    Vysotskaia, Valentina
    Li, Jonathan
    Zhao, Lora
    Wong, Mei
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [37] CABOZANTINIB (XL184) AT 40 MG IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC): RESULTS OF A PHASE 2 NON-RANDOMIZED EXPANSION COHORT (NRE)
    de Bono, J. S.
    Smith, M. R.
    Rathkopf, D.
    Corn, P. G.
    Mukherji, D.
    Harzstark, A. L.
    Sartor, O. A.
    Smith, D. C.
    Tunariu, N.
    Sweeney, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 296 - 296
  • [38] Potent antitumor activity of XL184 (cabozantinib), a c-MET and VEGFR2 inhibitor, in colorectal cancer patient-derived tumor explant models.
    Atreya, Chloe E.
    Song, Eun-Kee
    Messersmith, Wells
    Purkey, Alicia
    Bagby, Stacey
    Quackenbush, Kevin
    Kelley, Robin K.
    Kwak, Eunice
    Ryan, David
    Venook, Alan
    Arcaroli, John J.
    CANCER RESEARCH, 2013, 73 (08)
  • [39] Correlative tumor molecular profiling and plasma biomarker analysis in a phase II study of XL184 in patients with progressive or recurrent glioblastoma multiforme (GBM)
    DePrimo, S.
    Wu, B.
    Huang, S.
    Bautista, R.
    Cancilla, B.
    Vysotskaia, V.
    De Groot, J.
    Prados, M.
    Buller, R.
    Wen, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] The Involvement of Hepatocyte Growth Factor-MET-Matrix Metalloproteinase 1 Signaling in Bladder Cancer Invasiveness and Proliferation. Effect of the MET Inhibitor, Cabozantinib (XL184), on Bladder Cancer Cells
    Shintani, Terumichi
    Kusuhara, Yoshito
    Daizumoto, Kei
    Dondoo, Tsogt-Ochir
    Yamamoto, Hiroki
    Mori, Hidehisa
    Fukawa, Tomoya
    Nakatsuji, Hiroyoshi
    Fukumori, Tomoharu
    Takahashi, Masayuki
    Kanayama, Hiroomi
    UROLOGY, 2017, 101 : 169.e7 - 169.e13
12345